期刊
INTERNAL MEDICINE JOURNAL
卷 44, 期 6, 页码 597-600出版社
WILEY-BLACKWELL
DOI: 10.1111/imj.12415
关键词
vemurafenib; BRAF inhibitor; melanoma; secondary malignancy; pancreatic adenocarcinoma
资金
- Pfizer Australia
- Roche Australia
- Lilly Oncology
Vemurafenib is a tyrosine kinase inhibitor of BRAF that prolongs survival in patients with BRAF V600-mutant metastatic melanoma. Secondary cutaneous malignancies are a well-documented toxicity of vemurafenib, thought to be mediated by enhanced ERK signalling in BRAF wild-type, RAS-mutant cells. Vemurafenib could also promote growth of non-cutaneous secondary malignancies by a similar mechanism. We present a case of an individual who received vemurafenib for metastatic melanoma and experienced rapid growth of a pre-existing KRAS-mutant pancreatic adenocarcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据